Manufacturers should assess consumers’ use of products in “real world” settings early in the development process to minimize medication errors, FDA suggests in a draft guidance on safety considerations for product and container design.
Assessments early in development can help identify and reduce potential medication errors and avoid costly post-approval redesigns, the agency says in the